CSL Bioplasma is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. We also manufacture and market in vitro diagnostic products through Immunohaematology Vaccines & Pharmaceuticals We manufacture and provide influenza vaccine globally. In Australia...
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology.
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology.
Partner with CSL Seqirus CSL Vifor CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision he...
Negron先生还在其他领先的制药公司担任过高级职位,包括Valeant Pharmaceuticals, Novartis和McNeil Consumer Healthcare。| 因美纳因美纳Illumina副总裁兼全球高级科学主管Steven Barnard博士将担任其下一任首席技术官(CTO)。担任首席技术官的亚历克斯·阿拉瓦尼斯博士(Dr. Alex Aravanis)将离开因美纳。Barnard博士于1998年加入...
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients ...
此前,Collinson博士于2009年至2014年6月创立Opsonic Therapeutics并担任总裁兼首席执行官,此前,Collinson博士于2004年至2009年担任Rib-X Pharmaceuticals首席商务官,于2000年至2004年担任Phylos, Inc.业务发展高级副总裁,以及于1998年至2000年担任BASF Pharma全球研发许可副总裁。Collinson博士的科学家职业生涯始于ImmunoGen,...
2018年5月以2.71亿美元并购 haema,后者为主营采血中心服务。该公司不但生产用于临床中立即输血的血浆,还进一步加工在制药行业中用的血浆。2018年8月以2.86亿美元并购biotest pharmaceuticals公司,这次并购包含了22个生物监测血浆采集站。不难看出近期该公司通过垂直整合并购,进一步提升自己在血制品领域的霸主地位。
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology.
自2009年7月起,Collinson博士一直担任Theracos, Inc.的总裁兼首席执行官,该公司为一家专注于治疗糖尿病等疾病的新药研发公司。此前,Collinson博士于2009年至2014年6月创立Opsonic Therapeutics并担任总裁兼首席执行官,此前,Collinson博士于2004年至2009年担任Rib-X Pharmaceuticals首席商务官,于2000年至20...